Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Array Biopharma (ARRY), Puma Biotechnology (PBYI) and Amgen Inc (AMGN).
Array Biopharma (ARRY)
In a report released today, Varun Kumar from Cantor Fitzgerald initiated coverage with a Buy rating on Array Biopharma and a price target of $30. The company’s shares opened today at $18.17.
Kumar wrote:
“: We are initiating coverage of Overweight rating and 12-month price target of $30/share. We believe that the stock currently trades at a significant discount as its lead asset, Mektovi+Braftovi, still appears underappreciated by investors. Based on our discussion with KOLs and our market analysis, we believe that Array’s MEK/BRAFi combination has a best- in-class profile and is well-positioned commercially in BRAF-mutant melanoma and clinically in BRAF-mutant colorectal cancer.”
Array Biopharma has an analyst consensus of Strong Buy, with a price target consensus of $23, a 26.6% upside from current levels. In a report released today, Piper Jaffray also reiterated a Buy rating on the stock with a $28 price target.
See today’s analyst top recommended stocks >>
Puma Biotechnology (PBYI)
Cowen & Co. analyst Chris Shibutani maintained a Hold rating on Puma Biotechnology today and set a price target of $68. The company’s shares opened today at $22.82, close to its 52-week low of $17.60.
According to TipRanks.com, Shibutani is a 2-star analyst with an average return of 0.0% and a 40.0% success rate. Shibutani covers the Healthcare sector, focusing on stocks such as Syndax Pharmaceuticals Inc, Lexicon Pharmaceuticals, and Pieris Pharmaceuticals.
Puma Biotechnology has an analyst consensus of Hold, with a price target consensus of $43.
Amgen Inc (AMGN)
In a report released yesterday, Cory Kasimov from J.P. Morgan maintained a Hold rating on Amgen Inc. The company’s shares opened today at $196.30.
According to TipRanks.com, Kasimov is a 2-star analyst with an average return of 0.0% and a 40.6% success rate. Kasimov covers the Healthcare sector, focusing on stocks such as ACADIA Pharmaceuticals Inc, Allogene Therapeutics Inc, and Global Blood Therapeutics.
Amgen Inc has an analyst consensus of Moderate Buy, with a price target consensus of $211.90, which is a 7.9% upside from current levels. In a report issued on January 4, Citigroup also maintained a Hold rating on the stock with a $210 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
